CLAIMS

1. An intravaginal ring comprising a therapeutically effective amount of a non-hormonal active agent dispersed in an elastomer, wherein the non-hormonal active agent comprises a lactide component, and at least one selected from a copper component, or a zinc component.

2. The intravaginal ring of claim 1, wherein the non-hormonal active agent comprises a lactide component, a copper component, and a zinc component.

3. The intravaginal ring of claim 1 or 2, wherein the copper component is metallic copper, copper oxide, a copper salt or a copper ion-ligand complex.

4. The intravaginal ring of any one of claims 1-3, wherein the zinc component is metallic zinc, zinc oxide or a zinc salt.

5. The intravaginal ring of any one of claims 1-4, wherein the lactide component is D-lactide, L-lactide, DL-lactide or lactic acid.

6. The intravaginal ring of any one of claims 1-5, wherein the elastomer is selected from silicone, polyethylene vinyl acetate copolymer (EVA), styrene-butadiene-styrene block copolymer, polyphosphazene, poly(isoprene), poly(isobutylene), polybutadiene, polyurethane, a nitrile rubber, a neoprene rubber, or a combination thereof.

7. The intravaginal ring of any one of claims 1-6, wherein the elastomer is included in an amount of about 50% to about 99% by a total weight of the intravaginal ring.

8. The intravaginal ring of any one of claims 1-7, wherein the intravaginal ring is in a form of a matrix, and the elastomer is silicone.

9. The intravaginal ring of any one of claims 1-7, wherein the intravaginal ring is in a form of an exposed-core, and the elastomer is polyethylene vinyl acetate or polyurethane.

10. The intravaginal ring of claim 3, wherein the copper salt is anhydrous copper sulfate or copper sulfate hydrate.

11. The intravaginal ring of claim 4, wherein the zinc salt is zinc acetate, zinc formate, zinc lactate, zinc chloride, zinc sulfate, zinc iodide, zinc citrate, or zinc orotate, each of which is in an anhydrous or a hydrate form.

12. The intravaginal ring of any one of claims 1-11, wherein the non-hormonal active agent is included in an amount of about 5wt% to about 50wt%, based on a total amount of the intravaginal ring.

13. The intravaginal ring of claim 2, having copper ions, zinc ions and lactic acid released in a molar ratio of 1:1:1 to 1:6:6 after an initial first day period.

14. The intravaginal ring of claim 2, having a release of copper ions at a rate of 2 mg/day to 31 mg/day during a 30-day period of use.

15. The intravaginal ring of claim 2, having a release of zinc ions at a rate of 1 mg/day to 17 mg/day during a 30-day period of use.

16. The intravaginal ring of claim 2, having a release of lactic acid at a rate of 12 mg/day to 105 mg/day during a 30-day period of use.

17. The intravaginal ring of any one of claims 1-16, wherein said intravaginal ring is a contraceptive intravaginal ring for use in preventing and/or treating a disease caused by bacterial or viral infection.

18. Use of a therapeutically effective amount of a non-hormonal active agent dispersed in an elastomer, wherein the non-hormonal active agent comprises a lactide component, and at least one selected from a copper component, or a zinc component, in the preparation of a medicament, for the prevention and/or treatment of a disease caused by bacterial or viral infection, wherein the medicament is to be administered via an intravaginal ring as defined in any one of claims 1-16.

19. Method of preventing unintended pregnancy by applying the intravaginal ring of any one of claims 1-16 intravaginally to a female subject.

20. The intravaginal ring of claim 17 or use according to claim 18, wherein said disease is a sexually transmitted infection.